ABIOMED, Inc. (NASDAQ:ABMD) Director Paul Thomas sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $154.71, for a total transaction of $1,547,100.00. Following the completion of the transaction, the director now owns 12,172 shares in the company, valued at approximately $1,883,130.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of ABIOMED, Inc. (NASDAQ ABMD) traded down 0.94% during midday trading on Thursday, hitting $153.70. 125,036 shares of the stock were exchanged. The stock has a market cap of $6.75 billion, a P/E ratio of 89.88 and a beta of 0.20. ABIOMED, Inc. has a 12 month low of $95.14 and a 12 month high of $157.41. The firm has a 50 day moving average of $146.57 and a 200-day moving average of $131.84.

ABIOMED (NASDAQ:ABMD) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.03. The business had revenue of $132.47 million for the quarter, compared to the consensus estimate of $130.83 million. ABIOMED had a net margin of 16.13% and a return on equity of 13.03%. The company’s revenue for the quarter was up 28.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.29 EPS. Equities research analysts anticipate that ABIOMED, Inc. will post $2.24 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/abiomed-inc-abmd-director-paul-thomas-sells-10000-shares/1500659.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Teachers Advisors LLC boosted its stake in ABIOMED by 6.5% in the fourth quarter. Teachers Advisors LLC now owns 42,452 shares of the medical equipment provider’s stock worth $4,783,000 after buying an additional 2,608 shares in the last quarter. Creative Planning boosted its stake in ABIOMED by 16.4% in the first quarter. Creative Planning now owns 916 shares of the medical equipment provider’s stock worth $115,000 after buying an additional 129 shares in the last quarter. Bank of Montreal Can boosted its stake in ABIOMED by 48.7% in the first quarter. Bank of Montreal Can now owns 19,902 shares of the medical equipment provider’s stock worth $2,492,000 after buying an additional 6,520 shares in the last quarter. Capstone Asset Management Co. boosted its stake in ABIOMED by 2.8% in the first quarter. Capstone Asset Management Co. now owns 6,340 shares of the medical equipment provider’s stock worth $794,000 after buying an additional 170 shares in the last quarter. Finally, Louisiana State Employees Retirement System boosted its stake in ABIOMED by 2.0% in the first quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the medical equipment provider’s stock worth $1,277,000 after buying an additional 200 shares in the last quarter. 91.09% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have issued reports on the stock. William Blair restated an “outperform” rating on shares of ABIOMED in a research report on Thursday, June 8th. Zacks Investment Research upgraded shares of ABIOMED from a “hold” rating to a “strong-buy” rating and set a $163.00 price objective on the stock in a research report on Thursday, July 13th. BidaskClub cut shares of ABIOMED from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, June 28th. Piper Jaffray Companies set a $145.00 price objective on shares of ABIOMED in a research report on Tuesday, July 4th. Finally, Jefferies Group LLC boosted their price objective on shares of ABIOMED from $165.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, August 4th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. ABIOMED has an average rating of “Buy” and a consensus price target of $158.29.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Insider Buying and Selling by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.